11722604

pubmed:Citation

9

Huntington's disease is an autosomal dominant hereditary neurodegenerative disorder characterized by severe striatal cell loss. Dopamine (DA) has been suggested to play a role in the pathogenesis of the disease. We have previously reported that transgenic mice expressing exon 1 of the human Huntington gene (R6 lines) are resistant to quinolinic acid-induced striatal toxicity. In this study we show that with increasing age, R6/1 and R6/2 mice develop partial resistance to DA- and 6-hydroxydopamine-mediated toxicity in the striatum. Using electron microscopy, we found that the resistance is localized to the cell bodies and not to the neuropil. The reduction of dopamine and cAMP regulated phosphoprotein of a molecular weight of 32 kDa (DARPP-32) in R6/2 mice does not provide the resistance, as DA-induced striatal lesions are not reduced in size in DARPP-32 knockout mice. Neither DA receptor antagonists nor a N-methyl-d-aspartate (NMDA) receptor blocker reduce the size of DA-induced striatal lesions, suggesting that DA toxicity is not dependent upon DA- or NMDA receptor-mediated pathways. Moreover, superoxide dismutase-1 overexpression, monoamine oxidase inhibition and the treatment with the free radical scavenging spin-trap agent phenyl-butyl-tert-nitrone (PBN) also did not block DA toxicity. Levels of the antioxidant molecules, glutathione and ascorbate were not increased in R6/1 mice. Because damage to striatal neurons following intrastriatal injection of 6-hydroxydopamine was also reduced in R6 mice, a yet-to-be identified antioxidant mechanism may provide neuroprotection in these animals. We conclude that striatal neurons of R6 mice develop resistance to DA-induced toxicity with age.

eng

IM

MEDLINE

0953-816X

Print

NLM

1425-35

pubmed-meshheading:11722604-Aging, pubmed-meshheading:11722604-Animals, pubmed-meshheading:11722604-Ascorbic Acid, pubmed-meshheading:11722604-Dopamine, pubmed-meshheading:11722604-Dopamine and cAMP-Regulated Phosphoprotein 32, pubmed-meshheading:11722604-Dose-Response Relationship, Drug, pubmed-meshheading:11722604-Drug Resistance, pubmed-meshheading:11722604-Exons, pubmed-meshheading:11722604-Glutathione, pubmed-meshheading:11722604-Huntington Disease, pubmed-meshheading:11722604-Mice, pubmed-meshheading:11722604-Mice, Knockout, pubmed-meshheading:11722604-Mice, Transgenic, pubmed-meshheading:11722604-Microscopy, Electron, pubmed-meshheading:11722604-Neostriatum, pubmed-meshheading:11722604-Nerve Tissue Proteins, pubmed-meshheading:11722604-Neurons, pubmed-meshheading:11722604-Neurotoxins, pubmed-meshheading:11722604-Oxidative Stress, pubmed-meshheading:11722604-Oxidopamine, pubmed-meshheading:11722604-Phosphoproteins, pubmed-meshheading:11722604-Quinolinic Acid, pubmed-meshheading:11722604-Retrograde Degeneration, pubmed-meshheading:11722604-Substantia Nigra, pubmed-meshheading:11722604-Superoxide Dismutase, pubmed-meshheading:11722604-Uric Acid

Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.

Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't